Sab Biotherapeutics(NASDAQ) SABSW

Market CapN/A

Since IPO (2021)-98%

5 Year-95%

1 Year-8%

1 Month+158%

$0.02

-8.14%

-0.00Today

Sab Biotherapeutics last closing stock price
Metric	Price	Date
Last close	USD 0.03	2026-08-28

Sab Biotherapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-4.44%	USD 0.03	2026-08-21
1 month	+158%	USD 0.01	2026-07-29
3 month	+58.27%	USD 0.02	2026-05-26
Year to date	-17.31%	USD 0.03	2025-12-31
1 year	-7.86%	USD 0.03	2025-08-27
3 year	-65.6%	USD 0.08	2023-08-28
5 year	-95.47%	USD 0.57	2021-08-27
Since inception	-98.28%	USD 1.50	2021-02-09

Sab Biotherapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$12.78M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.35 (Low)

Dividend

$0.00

Beta (Volatility)

0.35 (Low)

Price

$0.02

Volume

17,636

Open

$0.02

Price

$0.02

Volume

17,636

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.03

52-Week Range

$0.00 - $0.20

Estimated Earnings Date

Nov 17, 2026

Dividend

$0.00

Beta (Volatility)

0.35 (Low)

Price

$0.02

Volume

17,636

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.03

52-Week Range

$0.00 - $0.20

Estimated Earnings Date

Nov 17, 2026

SABSW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sab Biotherapeutics

SAB Biotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative immunotherapies to address significant health challenges, including infectious and autoimmune diseases, as well as oncology. Founded in 2014 and headquartered in Sioux Falls, South Dakota, the company is dedicated to advancing its therapeutic candidates, such as SAB-142 for Type 1 diabetes, SAB-176 for seasonal influenza, and SAB-301 for MERS-CoV.

Products and Services

Immunotherapies targeting infectious diseases and autoimmune disorders
SAB-142: Anti-thymocyte globulin for Type 1 diabetes
SAB-176: Therapeutic candidate for seasonal influenza

Growth Outlook

Strong pipeline with multiple therapeutic candidates in development
Recent funding rounds have bolstered financial resources for R&D
Strategic partnerships may enhance market reach and product development

Financial Highlights

Recent quarterly net income of -$22.49 million, reflecting ongoing investment in R&D
Cash and short-term investments total $102.63 million, providing operational stability
Trailing twelve months (TTM) P/E ratio of 2.98 indicates potential for growth

SAB Biotherapeutics is positioned in the biotechnology sector, focusing on the development of groundbreaking therapies. The company’s commitment to addressing critical health issues through innovative solutions is evident in its diverse product pipeline. With a strong financial foundation, including significant cash reserves, SAB Biotherapeutics is well-equipped to navigate the challenges of drug development and commercialization. The recent financial performance highlights the company's ongoing investment in research and development, which is crucial for long-term growth and success in the competitive biopharmaceutical landscape.

AI Generated • Aug 21, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Miami Beach, FL 33140, US

SABSW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-6.74%

Return on Capital

-31.09%

Return on Assets

-5.36%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

17.64K

Avg. Volume

125.88K

Financials (TTM)

Gross Profit

-$2.28M

Operating Income

-$71.82M

EBITDA

-$9.46M

Operating Cash Flow

-$68.21M

Capital Expenditure

-$4.49M

Free Cash Flow

-$72.70M

Cash & ST Invst.

$102.63M

Total Debt

$5.13M

Sab Biotherapeutics Performance Analysis

Sab Biotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A
Q2	2026-06-30	N/A

Sab Biotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	153.2%
Q4	2025-12-31	-239.7%
Q1	2026-03-31	56.8%
Q2	2026-06-30	20.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$22.49M

-122.4%

EBITDA

-$21.63M

-134.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$102.63M

+1696.3%

Total Debt

$5.13M

-20.0%

Accounts Receivable

$1.84M

N/A

Inventory

$0.00

N/A

Long Term Debt

$4.49M

-17.7%

Short Term Debt

$641.00K

-33.5%

Return on Assets

-5.36%

N/A

Return on Invested Capital

-31.71%

N/A

Free Cash Flow

-$26.68M

-273.1%

Operating Cash Flow

-$24.11M

-237.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

VINCVincerx Pharma, Inc.

VINCVincerx Pharma, Inc.$0.01+3.15%

BACKIMAC Holdings, Inc.

BACKIMAC Holdings, Inc.$0.00+0.00%

BCTXWBriaCell Therapeutics Corp.

BCTXWBriaCell Therapeutics Corp.$0.00-0.00%

SYRSSyros Pharmaceuticals, Inc.

SYRSSyros Pharmaceuticals, Inc.$0.00+300.00%

OCEAOcean Biomedical, Inc.

OCEAOcean Biomedical, Inc.$0.00+0.00%

NUWENuwellis, Inc.

NUWENuwellis, Inc.$0.79-10.84%

REVBRevelation Biosciences, Inc.

REVBRevelation Biosciences, Inc.$1.00-4.76%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About SABSW

What is the current price of Sab Biotherapeutics?

Sab Biotherapeutics is trading at $0.02 per share.

What is the 52-week range for Sab Biotherapeutics?

Over the past 52 weeks, Sab Biotherapeutics has traded between $0.00 and $0.20.

How much debt does Sab Biotherapeutics have?

Sab Biotherapeutics total debt is unavailable.

How much cash does Sab Biotherapeutics have on hand?

Sab Biotherapeutics does not have cash on hand data available.

What is Sab Biotherapeutics’s dividend yield?

Sab Biotherapeutics does not currently have a dividend yield.

Sab Biotherapeutics(NASDAQ) SABSW

Sab Biotherapeutics Financials at a Glance

SABSW News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Sab Biotherapeutics

SABSW Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Sab Biotherapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About SABSW

What is the current price of Sab Biotherapeutics?

What is the 52-week range for Sab Biotherapeutics?

How much debt does Sab Biotherapeutics have?

How much cash does Sab Biotherapeutics have on hand?

What is Sab Biotherapeutics’s dividend yield?

Premium Investing Services